A single dose of the human papillomavirus vaccine confers protective immunity against infection on par with two doses, according to results from the NCI’s ESCUDDO trial, potentially making it easier ...

1Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. 2Division of Hematology/Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon. ...

1Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts. 2Massachusetts Eye and Ear, Boston, Massachusetts.

Major Finding: Iron activation within the lysosome triggers oxidative membrane lipid degradation and ferroptosis. Concept: Fentomycin-1 induces phospholipid oxidation and ferroptosis in cancer cells ...

Researchers found a treatable mechanism behind the cognitive problems that can follow CAR T-cell therapy, tracing them to overactive immune cells in the brain’s white matter. In mouse models, ...

Genentech will collaborate with Orionis Biosciences to discover and develop molecular glues for cancer, the companies announced today. Molecular glues are small molecules that bind to, and promote ...

Bristol Myers Squibb (Princeton, NJ), Princeton, NJ.

Findings from a multinational study suggest that adding an AI-integrated platform to training masterclasses for pathologists boosts their accuracy in classifying HER2-stained breast cancer samples, ...

Inavolisib (Itovebi; Genentech) boosted survival in patients with HR-positive, HER2-negative advanced breast cancer and extended the time they could wait before starting chemotherapy. In the phase III ...

Major Finding: An inflammatory signature is a prognostic biomarker for CAR T-cell failure in non-Hodgkin lymphoma. Concept: InflaMix uses results from common blood tests to predict survival and ...

Pfizer will acquire SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from the Chinese biopharmaceutical company 3SBio for $1.25 billion upfront and $4.8 billion more for meeting certain ...

Verastem’s avutometinib/defactinib combination earned FDA approval for KRAS-mutated low-grade serous ovarian cancer, marking the first treatment specifically for ...